



Cadila Healthcare Limited

Registered Office : Zydus Tower , Satellite Cross Roads, Ahmedabad - 380015.
Tel. No. (+91-79) 2686 8100 Fax No. : (+91-79) 2686 2365/66 Website : www.zyduscadila.com

Audited Financial Results for the quarter and year ended March 31, 2009.

CONSOLIDATED					Sr. No.	Particulars	COMPANY				
Rupees in Lacs [except for share data]							Rupees in Lacs [except for share data]				
9 Months Period ended on December 31, 2008 [Unaudited]	3 Months Period ended on March 31, 2009 [Audited]	Corresponding 3 Months Period ended in the previous year March 31, 2008 [Audited]	Year to date figures for the current year ended on March 31, 2009 [Audited]	Year to date figures for the previous year ended on March 31, 2008 [Audited]			9 Months Period ended on December 31, 2008 [Unaudited]	3 Months Period ended on March 31, 2009 [Audited]	Corresponding 3 Months Period ended in the previous year March 31, 2008 [Audited]	Year to date figures for the current year ended on March 31, 2009 [Audited]	Year to date figures for the previous year ended on March 31, 2008 [Audited]
					1	Sales & Income from operations :					
220686	71025	56716	291711	236380	A	Gross Sales	130134	43610	38124	173744	171914
4701	770	2028	5471	9777	B	Less : Excise Duty	3343	549	1187	3892	7713
215985	70255	54688	286240	226603	C	Net Sales	126791	43061	36937	169852	164201
4424	2085	1464	6509	5685	D	Other Income from Operations	19004	5716	3710	24720	10294
220409	72340	56152	292749	232288	E	Total sales and other income from operations	145795	48777	40647	194572	174495
					2	Expenditure :					
(7515)	2908	296	(4607)	(4552)	A	Increase [-] / Decrease [+] in stock in trade & work in progress	(830)	2622	968	1792	330
51359	15587	10604	66946	54060	B	Consumption of materials	37761	12075	9694	49836	45374
27608	5712	7609	33320	29520	C	Purchase of traded goods	10808	2542	3654	13350	17431
27711	7497	7036	35208	27656	D	Employees cost	17259	4544	5004	21803	19254
8042	3140	2251	11182	9687	E	Depreciation & Amortisation	5970	2286	1916	8256	7337
75583	25721	19434	101304	79785	F	Other Expenditure	49113	16650	14298	65763	58568
182788	60565	47230	243353	196156	G	Total Expenditure	120081	40719	35534	160800	148294
37621	11775	8922	49396	36132	3	Profit from Operations before Other Income, Interest & Exceptional Items	25714	8058	5113	33772	26201
1603	433	148	2036	1028	4	Other Income	5074	879	721	5953	4908
39224	12208	9070	51432	37160	5	Profit before Interest & Exceptional Items [3 + 4]	30788	8937	5834	39725	31109
5379	4399	1079	9778	5223	6	A Interest & financial charges	4052	3236	1117	7288	4348
3560	(1290)	470	2270	(1090)	B	Gain [-] / Loss [+] on Exchange Rate Fluctuations on Foreign Currency Loans	1402	112	467	1514	(1092)
8939	3109	1549	12048	4133	C	Total financial cost	5454	3348	1584	8802	3256
30285	9099	7521	39384	33027	7	Profit after Interest but before Exceptional Items [5 - 6]	25334	5589	4250	30923	27853
(182)	(2226)	0	(2408)	(691)	8	Exceptional Items	0	(1282)	0	(1282)	(484)
30103	6873	7521	36976	32336	9	Profit [+] / Loss [-] from Ordinary Activities before tax [7 + 8]	25334	4307	4250	29641	27369
5076	1582	2005	6658	6126	10	Tax expense	3000	50	710	3050	3750
25027	5291	5516	30318	26210	11	Net Profit [+] / Loss [-] from Ordinary Activities after tax [9 - 10]	22334	4257	3540	26591	23619
0	0	0	0	0	12	Extraordinary items [net of tax expense]	0	0	0	0	0
25027	5291	5516	30318	26210	13	Net Profit [+] / Loss [-] for the period [11 - 12]	22334	4257	3540	26591	23619
(519)	509	(320)	(10)	(451)	14	Adjustments on consolidation	0	0	0	0	0
24508	5800	5196	30308	25759	15	Net Profit [+] / Loss [-] for the period [13 + 14]	22334	4257	3540	26591	23619
6280	6820	6280	6820	6280	16	Paid-up equity share capital [Face Value Rs. 5 /-]	6280	6820	6280	6820	6280
			116700	99,940	17	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year				116460	99,100
17.95	4.25	4.14	22.20	20.51	18	Earnings Per Share [EPS] [For the period - not Annualised]:					
17.95	4.25	4.14	22.20	20.51	A	Basic and diluted EPS before Extraordinary items [Rs.]	16.36	3.12	2.82	19.48	18.80
					B	Basic and diluted EPS after Extraordinary items [Rs.]	16.36	3.12	2.82	19.48	18.80
35138950	34629818	35150458	34629818	35150458	19	Public shareholding :	35,138,950	34,629,818	35,150,458	34,629,818	35,150,458
27.97%	25.37%	27.98%	25.37%	27.98%		- Percentage of Shareholding	27.97%	25.37%	27.98%	25.37%	27.98%
					20	Promoters and Promoter group Shareholding :					
Nil	Nil	Nil	Nil	Nil	A	Pledged / Encumbered :					
N.A.	N.A.	N.A.	N.A.	N.A.		- Number of Shares	Nil	Nil	Nil	Nil	Nil
						- Percentage of shares	N.A.	N.A.	N.A.	N.A.	N.A.
						[as a % of the total shareholding of promoters and promoter group]					
N.A.	N.A.	N.A.	N.A.	N.A.		- Percentage of shares [as a % of the total share capital of the company]	N.A.	N.A.	N.A.	N.A.	N.A.
90474758	101869195	90463250	101869195	90463250	B	Non-encumbered :	90,474,758	101,869,195	90,463,250	101,869,195	90,463,250
100%	100%	100%	100%	100%		- Number of Shares	100%	100%	100%	100%	100%
						- Percentage of shares	100%	100%	100%	100%	100%
						[as a % of the total shareholding of promoters and promoter group]					
72.03%	74.63%	72.02%	74.63%	72.02%		- Percentage of shares [as a % of the total share capital of the company]	72.03%	74.63%	72.02%	74.63%	72.02%

Notes :

- [1] Pursuant to the amendments to Clause 41 of the Listing Agreement, the company has opted to publish only the consolidated results of the company. Investors can view the standalone results of the company on the company's website : www.zyduscadila.com and/or on the websites of BSE [www.bseindia.com] and/or NSE [www.nseindia.com].
- [2] The above audited results for the quarter and year ended March 31, 2009 were reviewed by the Audit Committee on April 27, 2009 and then approved by the Board of Directors at their meeting held on April 28, 2009.
- [3] In Consolidated Accounts, the accounts of foreign subsidiaries / a Joint Venture Company are audited up to December 31, 2008 / February 28, 2009 and subject to limited review by their auditors for the balance period up to March 31, 2009.
- [4] During the quarter, 90,000,000 equity shares of Rs. 5/- each were cancelled and 100,885,305 equity shares of Rs. 5/- each were issued simultaneously pursuant to Composite Scheme of Arrangement and as a result, the paid up capital of the Company is increased to 136,499,013 equity shares of Rs. 5/- each fully paid up.
- [5] Pursuant to Composite Scheme of Arrangement becoming effective, the Consumer Products Division of the Company was demerged and transferred to Carnation Nutra Analogue Foods Ltd. [Name changed to Zydus Wellness Ltd.], a subsidiary of the Company, with appointed date April 1, 2008 & therefore, the figures of the current period / year are not exactly comparable with those of the previous period / year.
- [6] Hitherto the Company used to follow AS-11 read with the Schedule VI to the Companies Act, 1956, and used to write off all the amount of exchange rate difference arising from " Long Term Foreign Currency Monetary Items " [LTFMCI] to the Profit & Loss Account. The Company has opted for accounting the exchange rate differences arising on the LTFMCI in accordance with the notification dated March 31, 2009 under the Companies [Accounting Standards] Amendment Rules, 2009 on Accounting Standard 11 relating to " the effects of changes in foreign exchange rates ". In view of above change in policy, consolidated net profit, net of tax, of the company for the year is higher by Rs. 945 Lacs.
- [7] The Board of Directors have recommended a dividend of Rs. 4.50 per equity share on the increased capital of 136,499,013 equity shares of Rs. 5/- each for the financial year ended March 31, 2009.
- [8] The status of investor complaints :
- [9] Pending at the beginning of the quarter - Nil, received and disposed off during the quarter - 19, pending at the end of the quarter - Nil.
- [9] The Company has one segment of activity viz. " Pharmaceuticals ".

By Order of the Board,
For Cadila Healthcare Limited,

Pankaj R. Patel
Chairman & Managing Director